No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 34 quarters in the window, leaving 17 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 6.7x · 10Y median 5.6x · 69th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:42:30.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Kiniksa Pharmaceuticals International, plc (KNSA) stock was $74.09 as of Oct 6, 2026, 10:40 AM EDT, down 2.91% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +97.6% · 3-year avg +67.1%/yr · 5-year avg +47.5%/yr
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Medical - Pharmaceuticals · London, GL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 27, 2026
21 days away
EPS Estimate
0.37
Revenue Est.
$259.65M
Last Quarter Results
EPS
$0.30
vs Estimate
$0.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KNSA | $5.65B | $74.09 | -2.91% | +97.61% | +47.48% | N/A | N/A |
| 2CGON | $5.71B | $64.74 | -5.78% | +72.10% | N/A | N/A | vs KNSA |
| 3MMED | $5.56B | $19.81 | -1.74% | N/A | N/A | N/A | vs KNSA |
| 4IOVA | $5.84B | $13.07 | -7.60% | +499.53% | -11.55% | +5.84% | vs KNSA |
| 5DOCS | $5.35B | $28.63 | +0.17% | -60.81% | -18.23% | N/A | vs KNSA |
| 6LGND | $5.95B | $296.69 | -3.29% | +69.07% | +30.72% | +17.12% | vs KNSA |
P/B RATIO
8.63
$243.60M
vs Estimate
$226.49M
Consensus Rating
Based on 8 analysts
Average Price Target
$98.00
+32.3% upside
Low
$87.00
Current
$74.09
High
$108.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.29 | $0.37 | $0.52 | 3 |
| Quarter ending Dec 2026 | $0.21 | $0.37 | $0.59 | 3 |
| Quarter ending Mar 2027 | $0.38 | $0.38 | $0.39 | 1 |
| Quarter ending Jun 2027 | $0.46 | $0.47 | $0.47 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.12 | $1.39 | $1.83 | 4 |
| FY 2027 | $1.24 | $2.05 | $3.05 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $259.56M | $259.65M | $259.73M | 5 |
| Quarter ending Dec 2026 | $273.81M | $276.16M | $278.51M | 5 |
| Quarter ending Mar 2027 | $285.85M | $288.39M | $291.58M | 4 |
| Quarter ending Jun 2027 | $303.98M | $306.68M | $310.07M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $991.19M | $993.65M | $996.10M | 6 |
| FY 2027 | $1.16B | $1.22B | $1.29B | 6 |
